Transcriptional Regulation of HMG-CoA Synthase and HMG-CoA Reductase Genes by Human ACBP

被引:39
|
作者
Vock, Christina [1 ]
Doering, Frank [1 ]
Nitz, Inke [1 ]
机构
[1] Univ Kiel, D-24118 Kiel, Germany
关键词
Cholesterol; Gene regulation; HNF-4; alpha; Promoter analysis;
D O I
10.1159/000185525
中图分类号
Q2 [细胞生物学];
学科分类号
071009 ; 090102 ;
摘要
The acyl-CoA binding protein (ACBP) is an ubiquitary expressed multi-functional protein which regulates basic cellular functions such as fatty acid and steroid metabolism. Since ACBP is described to interact with the transcription factor hepatocyte nuclear factor 4 alpha (HNF-4 alpha), we investigated the role of human ACBP on transcriptional regulation of the putative HNF-4 alpha target gene HMG-CoA synthase 1 (HMGCS1). As shown by promoter-reporter assays ACBP represses the HNF-4 alpha-induced activity of a 617bp HMGCS1 promoter fragment by approximately 80% in HepG2 cells as well as in non-endodermal HeLa cells devoid of HNF-4 alpha. Interestingly, reporter assays without co-transfection of HNF-4 alpha revealed that ACBP reduces the activity of the HMGCS1 promoter by about 60 to 80% in both cell lines. Activities of 417bp and 317bp HMGCS1 promoter fragments were 2.5 to 4 fold decreased by ACBP. Concordantly, the levels of HMGCS1-mRNA and protein were diminished to 60% and 70% in ACBP-expressing HeLa cells, respectively. Additionally, ACBP reduces the promoter activity and the mRNA levels of the cholesterogenic HMG-CoA reductase (HMGCR). In conclusion, we provide evidence that ACBP is a transcriptional regulator of the HMGCS1 and HMGCR genes encoding rate-limiting enzymes of cholesterol synthesis pathway. Copyright (c) 2008 S. Karger AG, Basel
引用
收藏
页码:515 / 524
页数:10
相关论文
共 50 条
  • [21] Discordant regulation of HMG-CoA reductase and squalene synthase by endotoxin and cytokines
    Memon, RA
    Shechter, I
    Grunfeld, C
    Feingold, KR
    FASEB JOURNAL, 1997, 11 (09): : A962 - A962
  • [22] Various HMG-CoA reductase inhibitors
    Thiery, J
    Seidel, D
    INTERNIST, 1999, 40 (01): : 113 - 114
  • [23] DRUGS INHIBITING HMG-COA REDUCTASE
    ENDO, A
    PHARMACOLOGY & THERAPEUTICS, 1985, 31 (03) : 257 - 267
  • [24] HMG-CoA reductase inhibitors and the kidney
    Vito M. Campese
    Bassel Hadaya
    Josephine Chiu
    Current Hypertension Reports, 2005, 7 : 337 - 342
  • [25] HMG-CoA reductase inhibitors and apoptosis
    Senatore, M
    Buemi, M
    NEPHRON, 1999, 81 (04): : 439 - 440
  • [26] Comparing HMG-CoA reductase inhibitors
    Jones, PH
    CLINICAL CARDIOLOGY, 2003, 26 (01) : I15 - I20
  • [27] ORIENTATION OF MICROSOMAL HMG-COA REDUCTASE
    PHILLIPS, CE
    NESS, GC
    FEDERATION PROCEEDINGS, 1983, 42 (07) : 1994 - 1994
  • [28] HMG-COA REDUCTASE INHIBITORS AND SLEEP
    SPIELBERG, SP
    TOBERT, JA
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 1992, 52 (01) : 109 - 110
  • [29] Diplopia and HMG-CoA reductase inhibitors
    Fraunfelder, FW
    Fraunfelder, FT
    Edwards, R
    JOURNAL OF TOXICOLOGY-CUTANEOUS AND OCULAR TOXICOLOGY, 1999, 18 (04): : 287 - 289
  • [30] HMG-CoA reductase inhibitors and myotoxicity
    Ucar, M
    Mjörndal, T
    Dahlqvist, R
    DRUG SAFETY, 2000, 22 (06) : 441 - 457